(Circulation. 2000;102:2952.)
© 2000 American Heart Association, Inc.
Clinical Investigation and Reports |
From the Mid America Heart Institute (S.P.M.), Saint Lukes Hospital, Kansas City, Mo; the Department of Cardiology (D.L.B., E.J.T.) and the Department of Biostatistics and Epidemiology (P.L.H.), The Cleveland Clinic Foundation, Cleveland, Ohio; the Ottawa Heart Institute (M.L.), Ottawa, Canada; the Division of Cardiology (M.T.R., R.M.C., R.A.H.), Duke Clinical Research Institute, Durham, NC; the Division of Cardiology (N.S.K.), Baylor College of Medicine, Houston, Tex; the Sanger Clinic (C.D.), Charlotte, NC; and Erasmus University (M.L.S.), Rotterdam, the Netherlands.
Correspondence to Steven P. Marso, MD, Mid America Heart Institute, 4401 Wornall Rd, Kansas City, MO 64111. E-mail smarso{at}saint-lukes.org
BackgroundPatients with a recent episode of nonST-segment elevation acute coronary syndrome before CABG have higher rates of operative morbidity and mortality than patients with stable coronary syndromes. The efficacy of administering eptifibatide to these patients undergoing in-hospital CABG is unknown.
Methods and ResultsThe Platelet Glycoprotein IIb-IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) trial randomized 10 948 patients to receive either eptifibatide or placebo. There were 1558 study participants who underwent in-hospital CABG: 692 received placebo, and 866 received eptifibatide. The main substudy analysis end point was death or myocardial infarction (MI) rates at the 6-month follow-up. The 30-day death or MI rates were 30.8% and 26.1% for the placebo and eptifibatide groups, respectively (P=0.041). The benefit of eptifibatide administration persisted through 6-months of follow-up (32.7% versus 27.6% for placebo versus eptifibatide, respectively; P=0.029). There was a greater reduction in the 6-month death or MI rate for patients who received eptifibatide within 72 hours of CABG (33.6% versus 23.8%; P=0.002) compared with the >72-hour group (31.6% versus 32%; P=1.0). The incidence of major bleeding was 56.6% for placebo-treated patients versus 58.2% for eptifibatide-treated patients (P=0.7).
ConclusionsEptifibatide administration in patients undergoing in-hospital CABG with a recent episode of a nonST-segment elevation acute coronary syndrome results in a significant reduction in death or MI that is evident at 7 days and persists through the 6-month follow-up without a significant increase in perioperative bleeding rates.
Key Words: coronary disease platelets grafting glycoproteins
This article has been cited by other articles:
![]() |
The Society of Thoracic Surgeons Blood Conservatio, V. A. Ferraris, S. P. Ferraris, S. P. Saha, E. A. Hessel II, C. K. Haan, B. D. Royston, C. R. Bridges, R. S.D. Higgins, G. Despotis, et al. Perioperative Blood Transfusion and Blood Conservation in Cardiac Surgery: The Society of Thoracic Surgeons and The Society of Cardiovascular Anesthesiologists Clinical Practice Guideline Ann. Thorac. Surg., May 1, 2007; 83(5_Supplement): S27 - S86. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. M. Dyke, L. K. Jennings, G. Maier, C. Andreou, R. Daly, and M. R. Tamberella III Preoperative Platelet Inhibition With Eptifibatide During Coronary Artery Bypass Grafting With Cardiopulmonary Bypass Journal of Cardiovascular Pharmacology and Therapeutics, March 1, 2007; 12(1): 54 - 60. [Abstract] [PDF] |
||||
![]() |
G A Large Contemporary management of acute coronary syndrome Postgrad. Med. J., April 1, 2005; 81(954): 217 - 222. [Abstract] [Full Text] [PDF] |
||||
![]() |
C. G. De Pasquale, A. D. Bersten, I. R. Doyle, P. E. Aylward, and L. F. Arnolda Infarct-induced chronic heart failure increases bidirectional protein movement across the alveolocapillary barrier Am J Physiol Heart Circ Physiol, June 1, 2003; 284(6): H2136 - H2145. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. S. Hochman and J. E. Tamis-Holland Acute Coronary Syndromes: Does Sex Matter? JAMA, December 25, 2002; 288(24): 3161 - 3164. [Full Text] [PDF] |
||||
![]() |
J. M. Albes, M. Gross, U. Franke, J. Wippermann, T. U. Cohnert, R. Vollandt, and T. Wahlers Revascularization during acute myocardial infarction: risks and benefits revisited Ann. Thorac. Surg., July 1, 2002; 74(1): 102 - 108. [Abstract] [Full Text] [PDF] |
||||
![]() |
M. Labinaz, R. Kilaru, K. Pieper, S. P. Marso, M. M. Kitt, M. L. Simoons, R. M. Califf, E. J. Topol, P. W. Armstrong, and R. A. Harrington Outcomes of Patients With Acute Coronary Syndromes and Prior Coronary Artery Bypass Grafting: Results From the Platelet Glycoprotein IIb/IIIa in Unstable Angina: Receptor Suppression Using Integrilin Therapy (PURSUIT) Trial Circulation, January 22, 2002; 105(3): 322 - 327. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. F. Khuri Evidence, sources, and assessment of injury during and following cardiac surgery Ann. Thorac. Surg., December 1, 2001; 72(6): S2205 - 2207. [Full Text] [PDF] |
||||
![]() |
V. Birjiniuk Patient outcomes in the assessment of myocardial injury following cardiac surgery Ann. Thorac. Surg., December 1, 2001; 72(6): S2208 - 2212. [Abstract] [Full Text] [PDF] |
||||
|
Circulation Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2000 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |